Reuters logo
BRIEF-Press release - Abeona Therapeutics announces approval of ABO-102 dose
2016年10月5日 / 中午12点02分 / 1 年前

BRIEF-Press release - Abeona Therapeutics announces approval of ABO-102 dose

Oct 5 (Reuters) - Abeona Therapeutics Inc :

* Abeona Therapeutics announces data safety monitoring board approves ABO-102 dose escalation for second cohort in phase 1/2 clinical trial for sanfilippo syndrome type A

* ABO-102 has been well tolerated through 30 day post-injection in subjects injected with low-dose

* DSMB authorized that clinical trial proceed with enrollment and dose escalation for second cohort

* High-Dose cohort will enroll up to 6 additional patients dosed at 1.0 x 10(13) vg/kg

* High-Dose cohort involves dosage at 1.0 x 10(13) vg/kg, twice the amount of ABO-102 received by patients in low-dose cohort Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below